Omnicell (NASDAQ:OMCL) Receives Buy Rating from Benchmark

Benchmark restated their buy rating on shares of Omnicell (NASDAQ:OMCL) in a research report report published on Tuesday, Benzinga reports. Benchmark currently has a $38.00 price target on the stock.

OMCL has been the subject of a number of other reports. Barclays began coverage on shares of Omnicell in a research note on Wednesday, January 3rd. They issued an underweight rating and a $33.00 price target for the company. Wells Fargo & Company decreased their target price on Omnicell from $28.00 to $26.00 and set an equal weight rating for the company in a research report on Friday, February 9th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, Omnicell currently has a consensus rating of Hold and an average price target of $42.20.

Omnicell Stock Performance

NASDAQ OMCL opened at $30.13 on Tuesday. Omnicell has a fifty-two week low of $25.69 and a fifty-two week high of $77.14. The stock has a 50 day simple moving average of $27.73 and a two-hundred day simple moving average of $31.80. The company has a current ratio of 2.38, a quick ratio of 2.22 and a debt-to-equity ratio of 0.48.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings results on Thursday, February 8th. The company reported $0.12 EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.22. The company had revenue of $258.85 million during the quarter, compared to analyst estimates of $256.00 million. Omnicell had a positive return on equity of 2.41% and a negative net margin of 1.91%. Research analysts forecast that Omnicell will post 0.09 earnings per share for the current year.

Hedge Funds Weigh In On Omnicell

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Covestor Ltd increased its position in Omnicell by 65.6% during the 3rd quarter. Covestor Ltd now owns 1,355 shares of the company’s stock valued at $61,000 after buying an additional 537 shares in the last quarter. Acadian Asset Management LLC purchased a new stake in shares of Omnicell in the third quarter worth $62,000. Neo Ivy Capital Management bought a new position in shares of Omnicell during the third quarter valued at $78,000. Fifth Third Bancorp raised its position in shares of Omnicell by 143.2% in the 3rd quarter. Fifth Third Bancorp now owns 2,230 shares of the company’s stock worth $100,000 after purchasing an additional 1,313 shares during the last quarter. Finally, Benjamin Edwards Inc. raised its position in shares of Omnicell by 36.4% in the 1st quarter. Benjamin Edwards Inc. now owns 3,253 shares of the company’s stock worth $95,000 after purchasing an additional 868 shares during the last quarter. Institutional investors own 97.70% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.